Skip to content

Services
Choose the pressure point closest to the decision your team needs to make.
Submission & CMCPathway, dossier, evidence, control strategy, or Module 3 readiness.Quality & Data IntegrityGMP remediation, audit trails, completeness, governance, or controls.Inspection & EnforcementReadiness, response, remediation, verification, or sustainment.AI-Enabled CMCStructured CMC data, regulatory modernization, digital governance, and decision support.
Explore all services Start with your situation
Who We Help
Insights
Intelligence hubs
Insights HubThe starting point for XGene analysis and intelligence.Regulatory Intelligence CenterSearch governed regulatory findings, guidance, and related evidence.CMC IntelligenceEvidence connected across the product lifecycle.
Analysis & resources
Articles & Case StudiesSenior-authored analysis with applied regulatory context.Regulatory RecordsBrowse the governed primary-source record archive.Resource CenterStructured reference tools and practical resources.
Media & practical answers
PodcastExpert conversations connecting evidence, judgment, and action.VideoVisual briefings that make regulated systems easier to understand.FAQsConcise answers that orient a regulatory, CMC, quality, or inspection question.
Featured AnalysisThe ICH Q11 Three-Part Justification — What FDA and EMA Require for Starting Material Designation and Where Programs Fall ShortXGene analysis · Aug 22, 2026Read Article →
About
- Methodology
Contact
Book a Call
Discuss a Project

Services
Choose the pressure point closest to the decision your team needs to make.
Submission & CMCPathway, dossier, evidence, control strategy, or Module 3 readiness.Quality & Data IntegrityGMP remediation, audit trails, completeness, governance, or controls.Inspection & EnforcementReadiness, response, remediation, verification, or sustainment.AI-Enabled CMCStructured CMC data, regulatory modernization, digital governance, and decision support.
Explore all services Start with your situation
Who We Help
Insights
Intelligence hubs
Insights HubThe starting point for XGene analysis and intelligence.Regulatory Intelligence CenterSearch governed regulatory findings, guidance, and related evidence.CMC IntelligenceEvidence connected across the product lifecycle.
Analysis & resources
Articles & Case StudiesSenior-authored analysis with applied regulatory context.Regulatory RecordsBrowse the governed primary-source record archive.Resource CenterStructured reference tools and practical resources.
Media & practical answers
PodcastExpert conversations connecting evidence, judgment, and action.VideoVisual briefings that make regulated systems easier to understand.FAQsConcise answers that orient a regulatory, CMC, quality, or inspection question.
Featured AnalysisThe ICH Q11 Three-Part Justification — What FDA and EMA Require for Starting Material Designation and Where Programs Fall ShortXGene analysis · Aug 22, 2026Read Article →
About
- Methodology
Contact
Book a Call
Discuss a Project

CMC Intelligence

CMC evidence connected across the product lifecycle.

Move from development evidence and control strategy through Module 3, transfer, validation, global submissions, and lifecycle change.

Search this intelligence Related Service

CMC IntelligenceDecision

01Product

02Process

03Control

04Dossier

GMP & Part 211 Intelligence CMC Intelligence Inspection & Enforcement Intelligence Remediation Intelligence AI-Enabled CMC & Regulatory Operations Manufacturing & Lifecycle Intelligence

Decision lens

Read the evidence through the system it affects.

Each intelligence family keeps the source record connected to technical context and an action pathway.

01

Product

Start from evidence that can be traced.

02

Process

Place the signal in its technical and regulatory context.

03

Control

Compare related patterns before deciding.

04

Dossier

Connect the conclusion to execution and verification.

Current XGene intelligence

Start with evidence already in the platform.

Article OOS Root Cause Analysis — Moving Beyond ‘Analyst Error’ "Analyst error" is not a root cause — it is a conclusion in search of evidence, and FDA’s… 7 min read →

Article Chiral Drug Substances: Stereospecific Synthesis, Enantiomeric Purity, and the ICH Q6A Specification Strategy More than half of the small molecule drugs approved by FDA in any given year contain at least… 6 min read →

Article CAPA Effectiveness Verification — Closing the Loop FDA Actually Closes An FDA investigator reviewing your CAPA system is not interested in how many CAPAs you have opened —… 19 min read →

Article CareFusion 213, LLC (BD) Class I Recall — ChloraPrep Sterile Antiseptic Applicators: The Sterile Manufacturing System Failure Behind the Recall and What Every Aseptic Processing Director Must Address CareFusion 213, LLC, a subsidiary of Becton, Dickinson and Company (BD), has recalled two configurations of its BD… 6 min read →

Article Risk Assessment in GMP Remediation — The ICH Q9 Practical Application Most pharmaceutical quality risk assessments are produced in response to a regulatory request rather than to support a… 9 min read →

Article Polymorphism in Drug Substances: The ICH Q6A Decision Tree, Solid-State Characterization, and Process-Induced Form Conversion Risk A drug substance that exists as multiple crystalline forms — differing in lattice structure, thermodynamic stability, and solubility… 6 min read →

XGene Intelligence Discovery

Search this XGene intelligence domain.

Refine by evidence type, CMC discipline, authority, or search term and continue into connected content.

Search Content Domain CMC Authority Action Modality Region Sort

Loading governed XGene intelligence…

Use intelligence operationally

Move from source → interpretation → decision → execution.

Explore Related Service Discuss a Project

Regulatory and quality consulting for pharmaceutical, biotechnology, and medical-device organizations.

Services

Regulatory Strategy CMC & Module 3 Quality & Data Integrity Inspection Readiness AI-Enabled CMC

Insights

Insights Hub Regulatory Intelligence Center Articles & Case Studies CMC Intelligence Resource Center Podcast Video

Company

About XGene Who We Help Contact Book a Call Discuss a Project

© 2026 XGene LLC · XGene Consulting Services · Troy, Michigan Privacy & Cookies · Terms · Disclaimer · Accessibility

XGene Navigator

Find the right evidence, insight, or service.

Search XGene

Services Regulatory Evidence Analysis FAQs Resources Video Podcast

Start typing to search across XGene's public knowledge base.

Saved for later

My XGene Library

Save public XGene articles, records, resources, and services on this device for quick return.

Saved items

Recently viewed